Enteric Disease Testing Market Size & Growth Forecast 2026–2035, By Segments (Disease), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Enteric Disease Testing Market size was estimated at USD 4.08 Billion in 2025 and is projected to grow at a 2.7% CAGR from 2026 to 2035, attaining USD 5.33 Billion by 2035. The industry revenue for 2026 is assessed at USD 4.18 billion.
Get more details on this report
Request Free Sample ReportEnteric Disease Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 29.27% share in 2025, supported by advanced laboratory networks, high testing volumes, established molecular diagnostics, and routine hospital-based testing for gastrointestinal infections.
- Asia Pacific is forecast to grow at a 3.08% CAGR as diagnostic access improves, laboratory capacity expands, and healthcare providers increasingly adopt confirmed testing over symptom-based treatment approaches.
Segment Momentum
- Bacterial disease testing captured 62.48% of the market in 2025, supported by consistently high testing volumes, established diagnostic workflows, and the need for rapid identification to guide treatment and infection control.
- Parasitic testing is expanding rapidly because it addresses diagnostic needs for persistent or unexplained gastrointestinal symptoms when routine bacterial testing does not provide conclusive results.
Market Expansion Drivers
- Rising prevalence of enteric infections and outbreak incidence increasing diagnostic demand globally.
- Expansion of molecular diagnostics and rapid PCR-based gastrointestinal panel testing adoption.
- Government-led screening programs and early diagnosis awareness initiatives improving testing penetration.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major players in the enteric disease testing market include Abbott Laboratories (United States), Becton, Dickinson and Company (United States), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (United States), Cepheid, Inc. (United States), DiaSorin S.p.A. (Italy), Meridian Bioscience, Inc. (United States), Quest Diagnostics Incorporated (United States), Biomerica, Inc. (United States), Coris BioConcept SPRL (Belgium).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
Higher incidence of bacterial, viral, and parasitic gastrointestinal infections is pushing healthcare systems to test earlier and more broadly, especially when outbreaks create pressure to identify the causative pathogen quickly. In the enteric disease testing market, this shifts purchasing and utilization toward assays that can support routine diagnosis as well as surge testing during foodborne events, seasonal infection waves, and water contamination episodes. Laboratories, hospitals, and public health agencies respond by expanding test menus, increasing sample throughput capacity, and prioritizing methods that reduce time to detection, all of which is driving demand for the market through more frequent stool testing and faster diagnostic decision-making.
Expansion of molecular diagnostics and rapid PCR-based gastrointestinal panel testing adoption
The growing use of molecular platforms is changing how clinicians approach suspected enteric infections by making multi-pathogen detection faster, more standardized, and less dependent on sequential testing. For the enteric disease testing market, rapid PCR-based gastrointestinal panels are influencing market adoption because they fit hospital and reference laboratory workflows that need actionable results for treatment selection, isolation decisions, and antimicrobial stewardship. This technological shift is also redirecting spending from traditional culture-only approaches toward higher-value multiplex systems, reagents, and integrated instruments, supporting market expansion through recurring test volumes and broader use in acute care settings.
Government-led screening programs and early diagnosis awareness initiatives improving testing penetration
Public health programs that promote early detection of diarrheal disease and outbreak surveillance are widening access to diagnostic services, particularly in settings where testing was previously underused or delayed. In the enteric disease testing market, government-backed screening efforts, reimbursement support, and awareness campaigns influence physician ordering patterns and patient presentation behavior by encouraging confirmation of infection rather than relying only on symptomatic treatment. That practical shift strengthens market development by bringing more community clinics, public laboratories, and regional hospitals into formal testing pathways, increasing market penetration through routine surveillance and earlier case identification.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising incidence of enteric diseases in developing countries | 1.00% | Short term (≤ 2 yrs) | Asia Pacific, Latin America (spillover: North America) | High | Fast |
| Development of rapid diagnostic tests | 0.80% | Medium term (2–5 yrs) | Europe, Asia Pacific (spillover: North America) | Medium | Moderate |
| Adoption of preventive healthcare measures and vaccination | 0.50% | Long term (5+ yrs) | North America, Europe (spillover: Asia Pacific) | Medium | Slow |
| Rising prevalence of enteric infections and outbreak incidence increasing diagnostic demand globally | 2.30% | High | North America, Asia Pacific, Africa | High | Near Term |
| Expansion of molecular diagnostics and rapid PCR-based gastrointestinal panel testing adoption | 2.00% | High | North America, Europe, Asia Pacific | High | Mid Term |
| Government-led screening programs and early diagnosis awareness initiatives improving testing penetration | 1.80% | High | Global | Medium | Near Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 29.27% share of the enteric disease testing market in 2025, backed by well-established diagnostic laboratory networks, broad access to hospital-based testing, and routine use of advanced molecular and immunoassay methods in clinical practice. The region’s leadership is strengthened by high testing volumes driven by strong physician awareness, structured care pathways for gastrointestinal infections, and consistent demand for rapid identification of bacterial, viral, and parasitic causes of disease. In practice, this supports steady instrument utilization, repeat consumables demand, and ongoing adoption of efficient testing workflows across reference labs and acute care settings.
Asia Pacific is projected to expand at a 3.08% CAGR over the forecast period, with growth in the enteric disease testing market being fueled by improving diagnostic access and rising use of laboratory testing across densely populated healthcare systems. Expansion is closely tied to the practical need for faster detection of infectious outbreaks, broader deployment of modern diagnostic platforms, and increasing testing activity as healthcare providers move beyond symptom-based treatment toward more confirmed diagnosis. As hospitals and laboratories strengthen capacity, adoption is rising in ways that directly increase test volumes and support wider use of enteric panels and related assays.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Quality StandardsGermany prioritizes highly standardized laboratory testing supported by rigorous quality assurance practices. Diagnostic providers in Germany continue adopting advanced molecular assays that improve pathogen detection accuracy while strengthening public health surveillance.
France 🇫🇷
Public Health DiagnosticsFrance strengthens enteric disease testing through coordinated laboratory networks supporting food safety and infectious disease monitoring. French healthcare providers increasingly implement molecular testing solutions that enable timely clinical intervention and surveillance activities.
Italy 🇮🇹
Hospital Testing ModernizationItaly continues modernizing microbiology laboratories by incorporating automated and molecular enteric disease testing platforms. Healthcare facilities across Italy emphasize faster diagnostic turnaround and improved detection capabilities for gastrointestinal infections.
Japan 🇯🇵
Infection Surveillance SupportJapan focuses on early detection of enteric pathogens through advanced laboratory diagnostics and coordinated surveillance programs. Healthcare institutions continue investing in sensitive testing technologies that improve outbreak management and clinical decision-making.
South Korea 🇰🇷
Rapid Testing IntegrationSouth Korea expands the use of rapid molecular diagnostics across hospitals and clinical laboratories to accelerate enteric disease detection. The country's focus on laboratory modernization supports efficient identification of infectious agents and improved patient management.
United States 🇺🇸
Multiplex Diagnostics FocusThe U.S. emphasizes rapid molecular and multiplex diagnostic platforms that improve identification of gastrointestinal pathogens. Clinical laboratories increasingly adopt automated workflows to support faster diagnosis, infection control, and appropriate treatment decisions.
Segment Leadership and Growth Trends
Enteric Disease Testing Market Share (%), Disease, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportBacterial disease testing held the strongest position in the enteric disease testing market in 2025, accounting for a 62.48% share. This leadership is maintained through the high routine testing demand associated with common bacterial enteric infections, which keeps diagnostic volumes consistently elevated across clinical settings. In the enteric disease testing market, bacterial testing also benefits from established diagnostic workflows and the need for timely identification to support treatment decisions and infection control, reinforcing its dominant share.
Parasitic disease testing is emerging as the fastest-growing segment in the enteric disease testing market as diagnostic requirements expand beyond more routinely screened bacterial causes. Its momentum is backed by increasing attention to harder-to-detect gastrointestinal infections that often require more targeted evaluation when standard bacterial results are inconclusive. Compared with alternatives, parasitic testing is gaining traction because it addresses a diagnostic gap in patients with persistent or unexplained enteric symptoms, making it an increasingly important area of growth within the enteric disease testing market.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Disease | Bacterial, Viral, Parasitic | Bacterial | Parasitic |
Competitive Landscape and Market Positioning
1. Abbott Laboratories (United States)
2. Becton Dickinson and Company (United States)
3. bioMérieux SA (France)
4. Bio-Rad Laboratories Inc. (United States)
5. Cepheid Inc. (United States)
6. DiaSorin S.p.A. (Italy)
7. Meridian Bioscience Inc. (United States)
8. Quest Diagnostics Incorporated (United States)
9. Biomerica Inc. (United States)
10. Coris BioConcept SPRL (Belgium)
The enteric disease testing market is expanding due to increased focus on rapid pathogen detection and laboratory automation. Advanced diagnostic techniques are improving sensitivity and reducing testing time. The enteric disease testing market is also seeing development of multiplex testing solutions for broader disease identification. Rising global health surveillance needs are accelerating adoption across healthcare settings.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Gavi, UNICEF, WHO, FIND | Apr-24 | A coordinated global deployment of over 1.2 million cholera rapid diagnostic tests was initiated across multiple countries, including Malawi. Led by Gavi, UNICEF, WHO, FIND, and partners, the initiative enhances outbreak detection capacity and supports more effective cholera surveillance and vaccination planning. |
| Avacta | Jun-23 | Avacta acquired Coris Bioconcept as part of its strategy to transition into a pure-play biotech company. The acquisition consolidates its diagnostics portfolio and strengthens its focus on infectious disease testing capabilities within its remaining business structure. |
| SD Biosensor | Jan-23 | SD Biosensor, in partnership with SJL Partners, completed the acquisition of Meridian Bioscience, which subsequently ceased trading on NASDAQ. The acquired entity continues operations under new ownership, strengthening SD Biosensor’s position in molecular and infectious disease diagnostics. |
| Bio-Rad | Jun-21 | Bio-Rad partnered with Seegene to co-develop multiplex molecular diagnostic tests for use on its CFX96 Dx Real-Time PCR System. The collaboration enhances Bio-Rad’s syndromic testing capabilities and expands its molecular diagnostics portfolio for enteric disease applications. |
| Abbott | 2023 | Abbott expanded its molecular gastrointestinal testing capabilities, strengthening its infectious disease diagnostics portfolio. This development enhances its position in enteric disease testing through improved molecular assay coverage and broader clinical application reach. |
| BD | 2024 | BD introduced automated infectious disease diagnostic systems, improving laboratory workflow efficiency and supporting higher-throughput enteric disease testing. The initiative strengthens its competitive positioning in automated diagnostic platforms for clinical laboratories. |
| Cepheid | 2024 | Cepheid launched rapid multiplex enteric pathogen testing assays, expanding its molecular diagnostics portfolio for gastrointestinal infections. The development enhances rapid detection capabilities and supports improved clinical decision-making in enteric disease management. |
| BIOMÉRIEUX | 2025 | BIOMÉRIEUX expanded digital laboratory integration technologies to improve connectivity and workflow efficiency in diagnostic laboratories. This enhancement strengthens its molecular diagnostics ecosystem and supports more integrated enteric disease testing operations. |
| DiaSorin S.p.A. | 2025 | DiaSorin S.p.A. developed high-sensitivity gastrointestinal diagnostic assays, enhancing detection performance in enteric disease testing. This advancement supports improved diagnostic accuracy and strengthens its molecular and immunodiagnostic product portfolio. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Enteric Disease Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Enteric Disease Testing Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market size of enteric disease testing?
How is the enteric disease testing industry projected to perform over the next decade?
How is the adoption of molecular diagnostics reshaping testing workflows in the enteric disease testing market?
What impact are government-led screening programs having on enteric disease testing demand?
Why is bacterial disease testing the largest segment in the enteric disease testing market?
Why is parasitic disease testing the fastest-growing segment in the enteric disease testing market?
Why is North America the largest regional market for enteric disease testing?
What is driving enteric disease testing market growth in Asia Pacific?
Which organizations are considered leaders in the enteric disease testing landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization